Invesco
PLX icon

Invesco’s Protalix BioTherapeutics PLX Stock Holding History

Invesco’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.5K Sell
36,716
-10,686
-23% -$22.6K ﹤0.01% 3756
2026
Q1 		$103K Sell
47,402
-3,161
-6% -$7.84K ﹤0.01% 3622
2025
Q4 		$91K Buy
50,563
+5,560
+12% +$11.4K ﹤0.01% 3646
2025
Q3 		$99.9K Sell
45,003
-138
-0.3% -$225 ﹤0.01% 3683
2025
Q2 		$66.8K Buy
+45,141
New +$92.3K ﹤0.01% 3699
2024
Q2 		– Sell
-25,908
Closed -$32.6K – 3950
2024
Q1 		$32.6K Sell
25,908
-976
-4% -$1.46K ﹤0.01% 3826
2023
Q4 		$47.9K Sell
26,884
-29,531
-52% -$45.9K ﹤0.01% 3753
2023
Q3 		$93.6K Buy
56,415
+34,763
+161% +$62.4K ﹤0.01% 3726
2023
Q2 		$43.3K Buy
+21,652
New +$51.6K ﹤0.01% 3825
2019
Q1 		– Sell
-3,596
Closed -$11K – 3791
2018
Q4 		$11K Sell
3,596
-133
-4% -$632 ﹤0.01% 3776
2018
Q3 		$27K Sell
3,729
-564
-13% -$2.83K ﹤0.01% 3838
2018
Q2 		$18K Buy
+4,293
New +$19.1K ﹤0.01% 3838

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Invesco's PLX Position: Q2 2026 in Review

Invesco reduced its Protalix BioTherapeutics (PLX) stake by 23% in Q2 2026, selling an estimated $22.6K and leaving 36,716 shares worth $85.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3756.

Invesco first reported a position in PLX in Q2 2018 and has held it in 12 quarters since. The position peaked at $103K in Q1 2026. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Invesco held 36,716 shares of Protalix BioTherapeutics worth $85.5K as of Q2 2026.
  • Invesco sold 10,686 Protalix BioTherapeutics shares in Q2 2026, an estimated $22.6K.
  • Protalix BioTherapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3756 holding.
  • Invesco first reported a position in Protalix BioTherapeutics in Q2 2018 and has held it in 12 quarters since.
  • Invesco's Protalix BioTherapeutics position peaked at $103K in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.